The HepatAssist® Bioartificial Liver Support System: clinical study and pig hepatocyte process
- 1 March 1999
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 8 (3) , 229-235
- https://doi.org/10.1517/13543784.8.3.229
Abstract
Based on perfusion of patient plasma through a circuit incorporating a hollow fibre membrane cartridge containing porcine hepatocytes, a bioartificial support system, or HepatAssist® System, has been developed. Thirty-nine patients with acute liver failure (ALF) were treated in a Phase I multicentre clinical study. Thirty-two patients were bridged to orthotopic liver transplantation and six patients recovered without requiring a graft. Patient survival rate at one month was 90%. On the basis of these results, a multicentre Phase II/III, randomised, controlled, parallel group study of the HepatAssist® System, compared to standard care in ALF patients has been initiated.Keywords
This publication has 10 references indexed in Scilit:
- No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneysThe Lancet, 1998
- No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenograftsThe Lancet, 1998
- The management of acute liver failureAlimentary Pharmacology & Therapeutics, 1998
- No Moratorium on Clinical TrialsScience, 1998
- Call for moratorium on xenotransplantsNature, 1998
- Clinical Experience With a Bioartificial Liver in the Treatment of Severe Liver FailureAnnals of Surgery, 1997
- Infection of human cells by an endogenous retrovirus of pigsNature Medicine, 1997
- Automated Liver Cell Processing Facilitates Large Scale Isolation and Purification of Porcine HepatocytesAsaio Journal, 1995
- Acute Liver FailureNew England Journal of Medicine, 1993
- Use of Sorbent Columns and Haemofiltration in Fulminant Hepatic FailureBlood Purification, 1993